clinical trial · NCT06596135
Open-Label Extension Study of Setmelanotide
Obesity Associated With Defects in Leptin-melanocortin PathwaySetmelanotide
brief summary
This is an open-label extension study designed to evaluate the long-term safety and tolerability of continued setmelanotide treatment in male and female patients ≥2 years of age who have completed or transitioned from a previous study with setmelanotide for rare genetic, syndromic, or acquired diseases of obesity upstream of the MC4R pathway.
started
Oct 21, 2024
primary completion
Oct 30, 2027
completion
Oct 30, 2027
last updated
Sep 4, 2025
official title
Open-Label Extension Study of Setmelanotide in Patients With a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol